- Home
- BVS vs GYRE Comparison
BVS vs GYRE Comparison
Compare BVS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVS | GYRE |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.8M | 606.4M |
| IPO Year | 2016 | 2004 |
Fundamental Metrics
Financial Performance| Metric | BVS | GYRE |
|---|---|---|
| Price | $9.50 | $6.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $14.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 653.3K | 77.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $568,087,000.00 | $275,000.00 |
| Revenue This Year | $7.52 | $19.88 |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $232.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.81 | $5.44 |
| 52 Week High | $11.25 | $9.42 |
Technical Indicators
Market Signals| Indicator | BVS | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 54.60 |
| Support Level | $8.43 | $5.59 |
| Resistance Level | $11.00 | $6.66 |
| Average True Range (ATR) | 0.37 | 0.33 |
| MACD | 0.11 | 0.10 |
| Stochastic Oscillator | 79.41 | 76.89 |
Price Performance
Historical ComparisonAbout BVS Bioventus Inc.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.